Isosorbide Mononitrate Tablet Market Report 2026

The isosorbide mononitrate tablet market size has grown strongly in recent years. It will grow from $1.2 billion in 2025 to $1.26 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to rising prevalence of coronary artery disease, long-term use of nitrates in angina management, increasing aging population, availability of cost-effective generic drugs, expansion of hospital and retail pharmacy infrastructure.

The isosorbide mononitrate tablet market size is expected to see strong growth in the next few years. It will grow to $1.55 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to growth in chronic cardiovascular conditions, increasing demand for extended-release tablets, rising adoption of online pharmacies, improved diagnosis of angina and heart failure, expanding access to cardiovascular medicines in emerging markets. Major trends in the forecast period include long-acting cardiovascular maintenance therapies, rising preference for extended-release formulations, growing use of generic nitrate medications, improved patient adherence through once-daily dosing, expansion of online and retail pharmacy access.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the isosorbide mononitrate tablet market in the coming years. Cardiovascular diseases (CVDs) are a group of disorders that affect the heart and blood vessels, including coronary artery disease, heart failure, and hypertension. This rise in cardiovascular diseases is largely linked to unhealthy diets, which often contain high levels of saturated fats, trans fats, sodium, and added sugars, resulting in conditions such as obesity, high blood pressure, and elevated cholesterol levels. Isosorbide mononitrate tablets aid in managing cardiovascular diseases by relaxing and widening blood vessels, improving blood flow, reducing the heart’s workload, relieving chest pain (angina), lowering blood pressure, and enhancing oxygen delivery to the heart muscle. For example, in September 2025, the Global Burden of Disease study reported by the American College of Cardiology, a US-based nonprofit medical association and professional society for cardiologists, recorded 19.2 million cardiovascular disease deaths worldwide in 2023. Consequently, the growing prevalence of cardiovascular diseases is fueling the expansion of the isosorbide mononitrate tablet market.

The growth of the isosorbide mononitrate tablet market is expected to be driven by the increasing prevalence of online pharmacies going forward. Online pharmacies are digital platforms or websites that enable consumers to purchase prescription and over-the-counter medications via the internet. The growth of online pharmacies is largely attributed to rising consumer demand for convenience, affordability, and easy access to medications and healthcare products without the need to visit physical stores. They provide convenient access to isosorbide mononitrate tablets by offering home delivery, competitive pricing, and better availability, particularly for patients managing chronic conditions. For example, in May 2024, the World Health Organization, a Switzerland-based international public health agency, reported that the number of digital requests for repeat prescriptions through the National Health Service (NHS) App rose by over 45% in 2023, reaching 3.1 million requests per month. As a result, the growth of online pharmacies is contributing to the expansion of the isosorbide mononitrate tablet market.

Major companies in the isosorbide mononitrate tablet market are concentrating on developing innovative products such as extended-release (ER) formulations to improve patient adherence, deliver sustained therapeutic effects, and optimize treatment outcomes for conditions like angina pectoris. An extended-release formulation is an advanced drug delivery system designed to release medication gradually over a prolonged period, minimizing dosing frequency and maintaining stable blood levels. For example, in February 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, obtained approval from the United States Food and Drug Administration (USFDA) to manufacture and market isosorbide mononitrate extended-release tablets USP in strengths of 30 mg, 60 mg, and 120 mg. These tablets are indicated to prevent chest pain (angina) in patients with coronary artery disease and are equivalent to the reference listed drug (RLD), imdur extended-release tablets.

Major companies operating in the isosorbide mononitrate tablet market are Pfizer Inc., Merck & Co., Inc., AstraZeneca plc, Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Zydus Lifesciences Limited, Torrent Pharmaceuticals Ltd., Micro Labs Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Mylan N.V., Hikma Pharmaceuticals PLC, Sandoz International GmbH, Qilu Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group, Shandong Keyuan Pharmaceutical Co., Ltd.

North America was the largest region in the isosorbide mononitrate tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isosorbide mononitrate tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the isosorbide mononitrate tablet market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the isosorbide mononitrate tablet market by increasing the cost of imported active pharmaceutical ingredients and excipients used in tablet manufacturing. Immediate-release and extended-release tablet segments are affected, with asia-pacific and north america facing supply chain sensitivities due to cross-border sourcing of raw materials. However, tariffs have also encouraged domestic production of generic formulations and strengthened local pharmaceutical manufacturing, supporting long-term supply stability and pricing competitiveness.

The isosorbide mononitrate tablet market research report is one of a series of new reports that provides isosorbide mononitrate tablet market statistics, including isosorbide mononitrate tablet industry global market size, regional shares, competitors with a isosorbide mononitrate tablet market share, detailed isosorbide mononitrate tablet market segments, market trends and opportunities, and any further data you may need to thrive in the isosorbide mononitrate tablet industry. This isosorbide mononitrate tablet market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Isosorbide mononitrate tablet is a long-acting nitrate medication mainly used to prevent and manage chest pain (angina) related to coronary artery disease. It functions by relaxing and widening blood vessels, especially in the heart, which increases blood and oxygen flow while decreasing the heart's workload. Unlike fast-acting nitrates that provide immediate relief, isosorbide mononitrate is taken consistently as a maintenance therapy to lessen the frequency and intensity of angina episodes and enhance overall cardiovascular health.

The primary dosage forms of isosorbide mononitrate tablets include immediate-release tablets and extended-release tablets. Immediate-release tablets are formulated to dissolve quickly, allowing rapid absorption for prompt relief, particularly in cases such as angina. These tablets are used for various conditions, including angina pectoris, heart failure, and hypertension, and are available through multiple distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The isosorbide mononitrate tablet market consists of sales of dilatrate-SR, isochron, monoket, and imdur, pediatric and geriatric-adjusted tablets, and combination products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.